Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,170.00
Bid: 12,172.00
Ask: 12,174.00
Change: 108.00 (0.90%)
Spread: 2.00 (0.016%)
Open: 12,194.00
High: 12,266.00
Low: 12,054.00
Prev. Close: 12,062.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

European shares rise tentatively

Fri, 23rd Dec 2022 09:43

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

EUROPEAN SHARES RISE TENTATIVELY (0915 GMT)

European indices are enjoying a moderate lift this morning, as the STOXX 600 ticked up in the first hour of trading and is now around 0.28% higher.

The top riser of the index is Danish biotech Bavarian Nordic, with shares up 5.8% after the company said it had signed a deal worth up to $83 million with the U.S Department of Defense.

Swiss drugmaker Roche Holding is providing the biggest lift on a weighted basis, while French luxury company LVMH is one of the larger drags, along with ASML , Nestle and

Retail is the sector outperformer, up 0.7%, while travel and leisure and utilities are the worst off, down 0.1%-0.2%.

GRINCH (RE)APPEARS (0744 GMT)

Ignoring a hawkish Fed, investors attempted the briefest of Santa rallies this week but revised U.S. GDP data and relatively low claims for unemployment benefits have brought back worries of higher-for-longer interest rates.

And so the safe-haven U.S. dollar is back on the prowl, with Asian shares set to end in the red for a second straight week.

Investors will now focus on U.S. personal consumption expenditures data, due later on Friday, which will provide more clues on the direction of inflation as traders look ahead to 2023.

Some are clinging to the hope that central banks will likely pause interest rate hikes next year in the face of an economic slowdown.

But as Generali Investments strategists put it, central banks are still showing their teeth, committed to tackling inflation, and an outright policy pivot looks distant.

The yen managed to retain most of its gains against the dollar after the BOJ bombshell earlier this week, with data on Friday showing that Japan's consumer inflation hit a fresh 40-year high, adding to pressure on the central bank to alter its ultra-easy policy.

Meanwhile, COVID-19 infections in China are likely to hit their peak within a week, a health official said, as China's health system prepares for a surge in cases weeks after the country began dismantling its zero-COVID policy.

The saga around the collapse of the FTX crypto exchange rumbles on, with Sam Bankman-Fried released on a $250 million bond package while he awaits trial.

In the corporate world, chip stocks slumped worldwide after Micron's dour forecast on what the chipmaker called a "significant supply demand mismatch".

Tesla CEO and Twitter owner Elon Musk said he will not sell any more Tesla stock for about two years, as the EV maker's stock is on track for its worst-ever monthly performance.

Key developments that could influence markets on Friday:

Economic events: Spain Q3 GDP data, France November producer price data

'TIS THE SEASON AFTER ALL (0734 GMT)

European futures are rising around 0.3%, with the STOXX 600 set to wrap up the last week before Christmas in the green.

The London Stock Exchange will begin a market closing process from 1230 GMT today. European bourses remain open all day, barring Dublin, which also has a half day.

Though the index has added 0.59% since Monday, it is no where near enough to reverse the 3.2% drop last week amid a spate of central bank decisions and business activity data that pointed to a slowdown in growth.

The index remains 12.4% lower than where it started the year.

Attention is staying on China, which expects a peak in COVID-19 infections within a week, and on Japan, where the latest data showed core consumer inflation hitting a four-decade high.

Minutes on Friday showed Bank of Japan (BOJ) policymakers had discussed the potential market impact of a future exit from ultra-low interest rates, months before a surprise tweak to its yield control policy earlier this week.

More News
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more
25 Apr 2024 09:12

LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP

(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.

Read more
25 Apr 2024 08:38

AstraZeneca blows past analysts' estimates for Q1

(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Read more
25 Apr 2024 07:56

REPEAT: Miner Anglo American reviews takeover bid from rival BHP

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 07:52

Sanofi profit slips on generic competition and currency effects

April 25 (Reuters) - Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.